Cancer Res Treat.  2015 Apr;47(2):282-289. 10.4143/crt.2014.009.

Adjuvant Treatment Modalities, Prognostic Predictors and Outcomes of Uterine Carcinosarcomas

• Gungorduk
• Ozdemir A
• Ertas IE
• Gokcu M
• Telli E
• Oge T
• Sahbaz A
• Sayhan S
• Sanci M
• Harma M
• Ozalp S

• KMID: 2132807
• DOI: http://doi.org/10.4143/crt.2014.009

Abstract

PURPOSE
The purpose of this study is to evaluate the clinicopathological characteristics, treatment, and prognosis of uterine carcinosarcoma (UC).
MATERIALS AND METHODS
A retrospective review of three cancer registry databases in Turkey was conducted for identification of patients diagnosed with UC between January 1, 1996, and December 31, 2012. We collected clinicopathological data in order to evaluate factors important in disease- free survival (DFS) and overall survival (OS).
RESULTS
A total of 66 patients with UC with a median age of 65.0 years were included in the analysis. The median survival time of all patients was 37.5 months and the 5-year OS rate was 59.1%. In early stage patients (I-II) who received adjuvant chemotherapy (CT) with radiation therapy (RT), the median DFS and OS was 44 months and 55 months, respectively, compared to 34.5 months and 36 months, respectively, in patients who received adjuvant RT or CT alone (hazard ratio [HR], 1.4; 95% confidence interval [CI], 0.7 to 3.1 for DFS; p=0.23 and HR, 2.2; 95% CI, 0.9 to 5.3 for OS; p=0.03). In advanced stage patients (III-IV), the median DFS and OS of patients receiving adjuvant RT with CT was 25 months and 38 months, respectively, compared to 23.5 months and 24.5 months, respectively, in patients receiving adjuvant RT or CT alone (HR, 3.1; 95% CI, 0.6 to 16.0 for DFS; p=0.03); (HR, 3.3; 95% CI, 0.7 to 15.0 for OS; p=0.01). In multivariate analysis, advanced International Federation of Gynecology and Obstetrics (FIGO) stage and suboptimal surgery showed significant association with poor OS.
CONCLUSION
In patients with early or advanced stage UC, adjuvant CT with RT is associated with improved DFS and OS, as compared to CT or RT alone.

Keyword

Carcinosarcoma; Uterine neoplasms; Adjuvant chemotherapy; Adjuvant radiotherapy

MeSH Terms

Carcinosarcoma*
Chemotherapy, Adjuvant
Gynecology
Humans
Multivariate Analysis
Obstetrics
Prognosis
Radiotherapy, Adjuvant
Retrospective Studies
Turkey
Uterine Neoplasms

Figure

• 

  Fig. 1. (A) Disease-free survival curves according to treatment groups in eary International Federation of Gynecology and Obstetrics (FIGO) stage (I&II). (B) Overall survival curves according to treatment groups in eary FIGO stage (I&II). (C) Disease-free survival curves according to treatment groups in advanced FIGO stage (III&IV). (D) Overall survival curves according to treatment groups in advanced FIGO stage (III&IV).

Reference

References

1. Arrastia CD, Fruchter RG, Clark M, Maiman M, Remy JC, Macasaet M, et al. Uterine carcinosarcomas: incidence and trends in management and survival. Gynecol Oncol. 1997; 65:158–63.

2. Berek JS, Hacker NF. Berek and Hacker's gynecologic oncology. 5th ed. Philadelphia: Wolters Kluwer/Lippincott Williams;2010. p. 433–4.

3. Schweizer W, Demopoulos R, Beller U, Dubin N. Prognostic factors for malignant mixed mullerian tumors of the uterus. Int J Gynecol Pathol. 1990; 9:129–36.

4. Cimbaluk D, Rotmensch J, Scudiere J, Gown A, Bitterman P. Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets. Gynecol Oncol. 2007; 105:138–44.

5. Galaal K, Kew FM, Tam KF, Lopes A, Meirovitz M, Naik R, et al. Evaluation of prognostic factors and treatment outcomes in uterine carcinosarcoma. Eur J Obstet Gynecol Reprod Biol. 2009; 143:88–92.

6. Vorgias G, Fotiou S. The role of lymphadenectomy in uterine carcinosarcomas (malignant mixed mullerian tumours): a critical literature review. Arch Gynecol Obstet. 2010; 282:659–64.

7. El-Nashar SA, Mariani A. Uterine carcinosarcoma. Clin Obstet Gynecol. 2011; 54:292–304.

8. Sutton G, Kauderer J, Carson LF, Lentz SS, Whitney CW, Gallion H, et al. Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol. 2005; 96:630–4.

9. Kanthan R, Senger JL. Uterine carcinosarcomas (malignant mixed mullerian tumours): a review with special emphasis on the controversies in management. Obstet Gynecol Int. 2011; 2011:470795.

10. Park JY, Kim DY, Kim JH, Kim YM, Kim YT, Nam JH. The role of pelvic and/or para-aortic lymphadenectomy in surgical management of apparently early carcinosarcoma of uterus. Ann Surg Oncol. 2010; 17:861–8.

11. Nemani D, Mitra N, Guo M, Lin L. Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: a SEER analysis. Gynecol Oncol. 2008; 111:82–8.

12. Gonzalez Bosquet J, Terstriep SA, Cliby WA, Brown-Jones M, Kaur JS, Podratz KC, et al. The impact of multi-modal therapy on survival for uterine carcinosarcomas. Gynecol Oncol. 2010; 116:419–23.

13. Menczer J, Levy T, Piura B, Chetrit A, Altaras M, Meirovitz M, et al. A comparison between different postoperative treatment modalities of uterine carcinosarcoma. Gynecol Oncol. 2005; 97:166–70.

14. Wong L, See HT, Khoo-Tan HS, Low JS, Ng WT, Low JJ. Combined adjuvant cisplatin and ifosfamide chemotherapy and radiotherapy for malignant mixed mullerian tumors of the uterus. Int J Gynecol Cancer. 2006; 16:1364–9.

15. Arend R, Doneza JA, Wright JD. Uterine carcinosarcoma. Curr Opin Oncol. 2011; 23:531–6.

16. Garg G, Kruger M, Christensen C, Deppe G, Toy EP. Stage III uterine carcinosarcoma: 2009 International Federation of Gynecology and Obstetrics Staging System and Prognostic Determinants. Int J Gynecol Cancer. 2011; 21:1606–12.

17. Inthasorn P, Carter J, Valmadre S, Beale P, Russell P, Dalrymple C. Analysis of clinicopathologic factors in malignant mixed Mullerian tumors of the uterine corpus. Int J Gynecol Cancer. 2002; 12:348–53.

18. Ferguson SE, Tornos C, Hummer A, Barakat RR, Soslow RA. Prognostic features of surgical stage I uterine carcinosarcoma. Am J Surg Pathol. 2007; 31:1653–61.

19. Huang GS, Chiu LG, Gebb JS, Gunter MJ, Sukumvanich P, Goldberg GL, et al. Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma. Gynecol Oncol. 2007; 107:513–7.